Satsuma hits all-time high on promising migraine drug data

Satsuma Pharmaceuticals

29/01/2020 19:09

** Drug developer's  STSA.O  shares rise 8.16% to an
all-time high of $27.55 after data from early-stage study of its
treatment for migraine was published in a medical journal
    ** The study tested co's nasal powder STS101 in healthy
volunteers against Bausch Health Companies'  BHC.TO  Migranal
and direct doses of dihydroergotamine, a chemical used for
migraine treatment  urn:newsml:reuters.com:*:nGNXbMQmJj
    ** Satsuma says STS101 showed a favorable tolerability
profile in patients and expects the drug will help in rapid pain
relief 
    ** STS101 is being tested in an ongoing late-stage trial and
results are expected in later half of 2020
    ** Shares have risen ~63% since its IPO in Sep. 2019

 (Reporting by Mrinalika Roy in Bengaluru)
 ((within U.S. +1 646 223 8780))